葵花药业：复方聚乙二醇(3350)电解质散获得药品注册证书

Core Viewpoint - The announcement indicates that a subsidiary of the company has received approval from the National Medical Products Administration for the registration of a new drug, which is a significant development for the company's product portfolio [1] Group 1: Drug Approval Details - The approved drug is a compound polyethylene glycol (3350) electrolyte powder, classified as a Class 3 chemical prescription drug [1] - The main ingredients of the drug include polyethylene glycol 3350, sodium chloride, potassium chloride, and sodium bicarbonate, with a specification of 6.9g per bag [1] - The drug is indicated for the treatment of chronic constipation in children aged 1 to 11 years and fecal impaction in children aged 5 to 11 years [1] Group 2: Company Information - The marketing authorization holder and manufacturing entity for the drug is Qihua Pharmaceutical Group (Tangshan) Biopharmaceutical Co., Ltd [1]